Castle study shows DecisionDx -SCC test to guide radiation in cSCC reduces cost

Castle Biosciences announced the publication of a new study1 in The Journal of Clinical and Aesthetic Dermatology JCAD which found that using its DecisionDx-SCC test to guide ART decisions for patients with SCC could result in substantial Medicare healthcare savings of up to approximately $972M annually. “The implications of this study are significant, as evidenced by the opportunity to save our overburdened healthcare system hundreds of millions of dollars through use of the DecisionDx-SCC test to guide more risk-appropriate utilization of ART in patients with SCC,” said Ally-Khan Somani, M.D., Ph.D., lead author, director of Mohs micrographic, reconstructive surgery & cutaneous oncology at SkinMD LLC, and adjunct clinical assistant professor, Department of Dermatology & Otolaryngology-Head and Neck Surgery at Indiana University School of Medicine. “Above and beyond the considerable cost savings is the potential to truly improve SCC patient care by using the test’s results to provide added confidence in decisions to forgo radiation therapy when a patient’s risk of metastasis is low.”